Elmar Kraus analyst STIFEL

Currently out of the existing stock ratings of Elmar Kraus, 14 are a BUY (63.64%), 8 are a HOLD (36.36%).

Elmar Kraus

Work Performance Price Targets & Ratings Chart

Analyst Elmar Kraus, currently employed at STIFEL, carries an average stock price target met ratio of 68.75% that have a potential upside of 14.19% achieved within 181 days.

Elmar Kraus’s has documented 44 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ABBV, AbbVie at 01-May-2024.

Wall Street Analyst Elmar Kraus

Analyst best performing recommendations are on ABBV (ABBVIE).
The best stock recommendation documented was for LLY (ELI LILLY AND COMPANY) at 1/21/2022. The price target of $291 was fulfilled within 75 days with a profit of $55.48 (23.56%) receiving and performance score of 3.14.

Average potential price target upside

BIIB Biogen LLY Eli Lilly and Company AZN AstraZeneca PLC ADR GILD Gilead Sciences AMGN Amgen ABBV AbbVie JNJ Johnson & Johnson MRK Merck mpany

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$205

$81.47 (65.95%)

$225

7 days ago
(02-May-2025)

39/66 (59.09%)

$81.47 (65.95%)

121

Buy

$255

$131.47 (106.43%)

$300

7 days ago
(02-May-2025)

21/30 (70%)

$131.47 (106.43%)

200

Buy

$187

$63.47 (51.38%)

$300

7 days ago
(02-May-2025)

9/21 (42.86%)

$63.47 (51.38%)

260

Hold

7 days ago
(02-May-2025)

7/32 (21.88%)

$112.06 (70.95%)

255

Buy

$220

$96.47 (78.09%)

$298

7 days ago
(02-May-2025)

14/26 (53.85%)

$96.47 (78.09%)

228

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Elmar Kraus?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?